<![CDATA[Biotek-snakken — Maj 2022]]>Biotech Stocks Facing FDA Decision In May 2022 https://www.proinvestor.com/investornyt/816845/biotech-stocks-facing-fda-decision-in-may-2022

]]>https://dev.proinvestor.com/forum/topic/401419/biotek-snakken-maj-2022RSS for NodeSun, 07 Jun 2026 01:00:23 GMTMon, 02 May 2022 03:10:11 GMT60<![CDATA[Reply to Biotek-snakken — Maj 2022 on Tue, 31 May 2022 09:21:43 GMT]]>Fin præsentation om Saniona / ingen tvivl om aktien er alt for lavt prissat: https://www.youtube.com/watch?v=-EkN5W5mE2M

]]>https://dev.proinvestor.com/forum/post/8064749https://dev.proinvestor.com/forum/post/8064749Tue, 31 May 2022 09:21:43 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Tue, 31 May 2022 08:57:50 GMT]]>
Link Preview Image
Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 – Alligator Bioscience

ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...

favicon

(alligatorbioscience.se)

]]>https://dev.proinvestor.com/forum/post/8064745https://dev.proinvestor.com/forum/post/8064745Tue, 31 May 2022 08:57:50 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Tue, 31 May 2022 08:57:48 GMT]]>ATOR-1017 data:

]]>https://dev.proinvestor.com/forum/post/8064748https://dev.proinvestor.com/forum/post/8064748Tue, 31 May 2022 08:57:48 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Mon, 30 May 2022 11:31:51 GMT]]>Tak BioShare...

]]>https://dev.proinvestor.com/forum/post/8064744https://dev.proinvestor.com/forum/post/8064744Mon, 30 May 2022 11:31:51 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Mon, 30 May 2022 08:01:39 GMT]]>Rhovac - fase 2b med onilcamotide viste resultater som placebo.

]]>https://dev.proinvestor.com/forum/post/8064742https://dev.proinvestor.com/forum/post/8064742Mon, 30 May 2022 08:01:39 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Mon, 30 May 2022 07:56:25 GMT]]>Er der nogen der ved, hvad det er for et dansk, svensk biotekselskab der falder 90% idag.

]]>https://dev.proinvestor.com/forum/post/8064739https://dev.proinvestor.com/forum/post/8064739Mon, 30 May 2022 07:56:25 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Mon, 30 May 2022 05:25:09 GMT]]>Købsmulighed? XBRANE BIOPHARMA: PARETO SPÅR XLUCANE-FÖRSENING PÅ 2-4 MÅNADER
9:15
STOCKHOLM (Nyhetsbyrån Direkt) Biosimilarutvecklaren Xbrane Biopharma väntas få en försening på 2-4 månader enligt Pareto Securities.

Det framgår av en analyskommentar på måndagen.

Xbrane väntas enligt Pareto få en temporärt negativ kursreaktion på aktien som enligt analyshusets bedömning är kraftigt undervärderad.

Kursen i Xbrane har mer än halverats sedan utläsningen av bolagets fas 3-resultat påpekar Pareto.

]]>https://dev.proinvestor.com/forum/post/8064740https://dev.proinvestor.com/forum/post/8064740Mon, 30 May 2022 05:25:09 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Sat, 28 May 2022 11:21:20 GMT]]>Here's What AstraZeneca's Recent FDA News Means for Shareholders
https://www.proinvestor.com/investornyt/830734/heres-what-astrazenecas-recent-fda-news-means-for-shareholders

]]>https://dev.proinvestor.com/forum/post/8064738https://dev.proinvestor.com/forum/post/8064738Sat, 28 May 2022 11:21:20 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Sat, 28 May 2022 07:59:38 GMT]]>Men der står i overskriften preliminary data og cut-off stadig fra november 2021, så forhåbentlig ændrer det noget.

]]>https://dev.proinvestor.com/forum/post/8064747https://dev.proinvestor.com/forum/post/8064747Sat, 28 May 2022 07:59:38 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Sat, 28 May 2022 07:56:30 GMT]]>Nej og hvis dette er de tæt på endelige data, så er det som han skriver ved første øjekast dårligere end uden tislelizumab

]]>https://dev.proinvestor.com/forum/post/8064737https://dev.proinvestor.com/forum/post/8064737Sat, 28 May 2022 07:56:30 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Sat, 28 May 2022 07:25:31 GMT]]>Tak lahn1, han lader ikke til at være specielt begejstret for det han ser fra zani desværre. Vi må se når der kommer lidt mere opdateret. Kursmæssigt er det også fortsat begrænset med entusiasme. God weekend! 🙂

]]>https://dev.proinvestor.com/forum/post/8064741https://dev.proinvestor.com/forum/post/8064741Sat, 28 May 2022 07:25:31 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 12:30:53 GMT]]>Biotech Stocks Facing FDA Decision In June 2022
https://www.proinvestor.com/investornyt/830415/biotech-stocks-facing-fda-decision-in-june-2022

]]>https://dev.proinvestor.com/forum/post/8064736https://dev.proinvestor.com/forum/post/8064736Fri, 27 May 2022 12:30:53 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 12:17:21 GMT]]>Kan anbefale at følge @germanbiotech på twitter, har godt styr på Zyme og udviklingen indenfor HER2 kandidater

]]>https://dev.proinvestor.com/forum/post/8064734https://dev.proinvestor.com/forum/post/8064734Fri, 27 May 2022 12:17:21 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 11:48:11 GMT]]>Også spændende at All Blue har købt 500K flere aktier.

]]>https://dev.proinvestor.com/forum/post/8064746https://dev.proinvestor.com/forum/post/8064746Fri, 27 May 2022 11:48:11 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 08:34:41 GMT]]>Mon ikke data opdateres yderligere på ASCO, da cut-off var novemver 2021. Men data ser spændende ud 🙂

]]>https://dev.proinvestor.com/forum/post/8064743https://dev.proinvestor.com/forum/post/8064743Fri, 27 May 2022 08:34:41 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 07:42:09 GMT]]>Zyme med "one-to-one" på Jefferies Healthcare Conference 8. og 9. juni. Der er også ASCO 2022 Analyst & Investor Call den 6. juni - bliver spændende...også hvad næste træk fra AB eller andre bliver 🙂

]]>https://dev.proinvestor.com/forum/post/8064733https://dev.proinvestor.com/forum/post/8064733Fri, 27 May 2022 07:42:09 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Fri, 27 May 2022 04:49:30 GMT]]>Har Anavex Life Sciences (AVXL) potentialet til at stige 265 %, som Wall Street-analytikere forventer?

]]>https://dev.proinvestor.com/forum/post/8064735https://dev.proinvestor.com/forum/post/8064735Fri, 27 May 2022 04:49:30 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 19:25:22 GMT]]>Handler 7,2 after-hours med en pæn volume - men ikke vi har nogle shorts som snart gerne vil ud af den kattepine 🙂

]]>https://dev.proinvestor.com/forum/post/8064727https://dev.proinvestor.com/forum/post/8064727Thu, 26 May 2022 19:25:22 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 19:23:01 GMT]]>Zymeworks - dejligt med lidt gode nyheder for Zanidatamab. https://finance.yahoo.com/news/clinical-data-demonstrating-promising-antitumor-210000234.html

]]>https://dev.proinvestor.com/forum/post/8064729https://dev.proinvestor.com/forum/post/8064729Thu, 26 May 2022 19:23:01 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 03:13:06 GMT]]>
Link Preview Image
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ: RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously). The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is the leading oral drug in mid-to late-stage development with use in a broader population (not limited to refractory patients like JAKs) and with a clean safety

favicon

Yahoo Finance (finance.yahoo.com)

]]>https://dev.proinvestor.com/forum/post/8064730https://dev.proinvestor.com/forum/post/8064730Thu, 26 May 2022 03:13:06 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 03:12:38 GMT]]>Analytikerne mål stadig fine:

]]>https://dev.proinvestor.com/forum/post/8064732https://dev.proinvestor.com/forum/post/8064732Thu, 26 May 2022 03:12:38 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 03:11:53 GMT]]>
Link Preview Image
RAPT Therapeutics Announces Private Placement Financing of $50 Million

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants to purchase up to 4 million shares of its common st

favicon

Yahoo Finance (finance.yahoo.com)

]]>https://dev.proinvestor.com/forum/post/8064724https://dev.proinvestor.com/forum/post/8064724Thu, 26 May 2022 03:11:53 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Thu, 26 May 2022 03:09:57 GMT]]>RAPT Therapeutics henter lidt penge ganske givet for at stå stærkere økonomisk i de partnerforhandlinger der forhåbentlig pt foregår med RPT193

]]>https://dev.proinvestor.com/forum/post/8064725https://dev.proinvestor.com/forum/post/8064725Thu, 26 May 2022 03:09:57 GMT<![CDATA[Reply to Biotek-snakken — Maj 2022 on Wed, 25 May 2022 10:42:30 GMT]]>LP90- Jeg har ikke rigtig kunne finde det nogen steder. Det er en aktie, som kører frem og tilbage, selv uden dårlige eller gode nyheder.

]]>https://dev.proinvestor.com/forum/post/8064726https://dev.proinvestor.com/forum/post/8064726Wed, 25 May 2022 10:42:30 GMT